HOME / INSIGHTS / TMDA

New eCTD validation criteria: what changes for importers from July

TMDA's updated technical validation checklist tightens Module 1 metadata and changes how regional administrative documents are indexed. Submissions that passed screening in May will fail it in July. Here's the practical difference.

If you import or hold marketing authorisations in Tanzania, the July checklist revision is the kind of change that looks clerical and behaves expensive. Nothing about the science of your dossier changes; what changes is whether the dossier gets read at all. Validation is the gate before assessment — fail it and your submission date no longer exists.

We've compared the outgoing and incoming checklists line by line. Three changes matter in practice; the rest is renumbering.

1. Module 1 metadata is now machine-checked

Until now, mismatches between the envelope metadata and the administrative documents inside Module 1 were caught — or not — by a human screener. From July, the eCTD envelope is validated automatically against the application form fields. The product name, strength, dosage form and applicant name must match character for character.

The most common failure we anticipate: applicants whose legal name on the BRELA certificate differs from the name on the application form ("Ltd" against "Limited" is enough). Fix the source documents now, not the week of submission.

What we're doing about it: every dossier in our pipeline gets a metadata reconciliation pass against the new schema before submission. If you hold authorisations you manage yourself, run the same check — the schema is in the annex of the July guidance.

2. Regional administrative documents move

Power of attorney, GMP certificates and certificates of pharmaceutical product relocate from section 1.2 to a new 1.4 structure aligned with the EAC common format. Resubmissions and variations filed after the cutover must use the new structure even if the original dossier used the old one — there is no grandfathering.

3. Lifecycle sequences get stricter

Variation sequences must now reference the exact sequence number they modify. Submitting a variation against "the current dossier" without the reference will fail validation. If your dossier history is untidy — sequences filed by different consultants over the years — reconstruct the sequence log before your next variation, or the variation will bounce.

The dates that matter

DateWhat happens
16 JUN 2026Last day TMDA accepts submissions validated against the old checklist
01 JUL 2026New validation criteria in force for all new submissions
01 SEP 2026New criteria extend to variations and renewals on existing authorisations

If you have a submission ready now, file before mid-June and you're assessed under the old rules end to end. If you'll miss that window, don't rush a weak dossier in — a validation pass under the new rules is cheaper than a rejection under the old ones.

If you'd rather not manage this yourself

This is exactly the class of change our retainer clients never hear about until it's already handled. Our schedule of services covers it, and the first consultation costs nothing.

Bring us a product. We'll map its route to approval.

A first consultation costs nothing: we review where your product stands, what the regulator will ask, and how long the road realistically is.

Book a consultation

Or write to info@pharmasolutionshub.com — we reply within one business day.